Alex Zhavoronkov, a pioneer in AI-driven drug discovery, presented an engaging talk at ARDD2024. He explored the convergence of ageing research, biotechnology, and artificial intelligence, highlighting the potential of integrating epigenetic data with advanced AI models to identify therapeutic targets. His talk emphasized breakthroughs in ageing clocks and their implications for longevity science.

Key Points:

Alex Zhavoronkov's talk illustrated the transformative potential of integrating AI and epigenetics in drug discovery, marking a new era for ageing research. By bridging scientific breakthroughs and commercial application, he envisions a future where ageing is effectively targeted and managed for healthier, longer lives.

• Revolutionizing Ageing Research with Epigenetics: Zhavoronkov discussed how advancements in methylation ageing clocks, once dismissed as simple biomarkers, are now revealing therapeutic targets for ageing-related diseases, thanks to groundbreaking research and improved AI tools.
• Integration of AI in Drug Discovery: His company, Insilico Medicine, leverages AI-driven models like "Precious 3 GPT" to synthesize biological data and identify novel drug targets. These models utilize multi-omics data to predict age, disease, and therapeutic opportunities.
• Therapeutic Targets from Ageing Clocks: Recent studies demonstrate the potential of DNA methylation clocks to uncover druggable targets, including key proteins like TINIC and CAT6B. These findings are transforming the perception of ageing clocks as tools for therapeutic innovation.
• Success Stories in AI-Driven Drug Development: Zhavoronkov highlighted Insilico Medicine’s achievements, including advancing nine programs to clinical trials and securing substantial deals with pharmaceutical companies, demonstrating the commercial and scientific viability of AI-driven drug discovery.
• Sustainability and Ageing Research: He underscored the importance of sustainability in the longevity field, advocating for decarbonization and leveraging drug discovery technologies for environmental benefits, such as CO2 capture.
• Collaboration and Future Prospects: The presentation concluded with a call to action for greater collaboration between academia and industry. Zhavoronkov also announced new partnerships, emphasizing the importance of collective efforts in accelerating longevity science.